Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- intolerância ao calor
- sudorese
- perda de peso
- palpitações
- tremor
- bócio difuso
- orbitopatia
Outros fatores diagnósticos
- irritabilidade
- sopro cardíaco
- pele úmida e aveludada
- queda de cabelos
- fraqueza muscular
- sopro tireoidiano
- onicólise
- vitiligo
- mixedema pré-tibial
- acropaquia
- irregularidade menstrual
- disfunção sexual
Fatores de risco
- história familiar de doença tireoidiana autoimune
- sexo feminino
- tabagismo
- ingestão elevada de iodo
- terapia com lítio
- agente biológico e terapias com citocina
- radiação
- radioterapia com iodo para bócio nodular benigno
- estresse
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- hormônio estimulante da tireoide (TSH)
- T4 sérico livre ou total
- T3 total ou livre sérico
- anticorpos antirreceptor de hormônio estimulante da tireoide (TSH [TRAb])
Investigações a serem consideradas
- cálculo da razão T3/T4 ou T3L/T4L total
- captação de iodo radioativo ou tecnécio-99
- cintilografia da tireoide
- anticorpos antitireoperoxidase (TPOAb)
- ultrassonografia da tireoide
- tomografia computadorizada (TC) ou ressonância nuclear magnética (RNM) da órbita
- biópsia de pele
Algoritmo de tratamento
tempestade tireoidiana
doença de Graves subclínica
adultos sintomáticos não lactantes e não gestantes
gestantes
crianças
Colaboradores
Autores
Salman Razvi, MD
Consultant Endocrinologist and Senior Lecturer
Translational and Clinical Research Institute, Queen Elizabeth Hospital, Gateshead
Newcastle University
Newcastle upon Tyne
UK
Declarações
SR has received speaker fees from Merck, IBSA, and Abbott Pharmaceuticals Ltd., all makers of levothyroxine. In addition, SR is in receipt of funding for an investigator-initiated trial from Merck to study the role of thyroid hormones in heart failure.
Agradecimentos
Dr Salman Razvi would like to gratefully acknowledge Dr Petros Perros, Dr Douglas S. Ross, Dr George Hennemann, and Dr Vahab Fatourechi, previous contributors to this topic.
Declarações
PP, DSR, GH, and VF are authors of references cited in this topic.
Revisores
Elizabeth N. Pearce, MD
Associate Professor of Medicine
Boston University Medical Center
Boston
MA
Disclosures
ENP is a consultant for Scientific Consulting Company GmbH and a management council member for the Iodine Global Network.
Kristien Boelaert, MD, PhD, FRCP
Reader in Endocrinology
Institute of Metabolism and Systems Research
College of Medical and Dental Sciences
University of Birmingham
Birmingham
UK
Disclosures
KB declares that she has no competing interests.
Paul Carroll, MD, FRCP
Clinical Lead for Endocrinology
Chair of Thyroid MDM
Guy’s and St Thomas’ NHS Trust
London
UK
Disclosures
PC declares that he has no competing interests.
David Cooper, MD
Division Head
Endocrinology
Sinai Hospital of Baltimore
Baltimore
MD
Disclosures
DC declares that he has no competing interests.
Differentials
- Bócio nodular tóxico
- Tireoidite indolor e pós-parto
- Hipertireoidismo gestacional
More DifferentialsGuidelines
- Thyroid disease in pregnancy
- Practice parameter for treatment of benign and malignant thyroid disease with I-131 sodium iodide
More GuidelinesPatient information
Graves’ disease
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer